20/20 Biolabs, Inc.
AIDX
$0.52
$0.000.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 106.73% | -34.35% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 106.73% | -34.35% | |||
| Cost of Revenue | 46.57% | -28.78% | |||
| Gross Profit | 384.42% | -51.76% | |||
| SG&A Expenses | -4.55% | 48.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.91% | 23.82% | |||
| Operating Income | 13.80% | -58.13% | |||
| Income Before Tax | 30.74% | -66.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 30.74% | -66.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 30.74% | -66.29% | |||
| EBIT | 13.80% | -58.13% | |||
| EBITDA | 14.10% | -59.67% | |||
| EPS Basic | 7.87% | -9.49% | |||
| Normalized Basic EPS | 50.87% | -12.34% | |||
| EPS Diluted | 6.10% | -8.97% | |||
| Normalized Diluted EPS | 50.87% | -12.34% | |||
| Average Basic Shares Outstanding | 40.92% | 48.06% | |||
| Average Diluted Shares Outstanding | 40.92% | 48.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||